Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly
BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h6778 (Published 15 December 2015) Cite this as: BMJ 2015;351:h6778- Pieter van Eijsden
- 1Amsterdam
The future of a newly licensed drug to treat lung cancer hangs in the balance in the Netherlands after the country’s National Health Care Institute (ZIN) found that its cost would be €134 000 (£97 000; $150 000) per quality adjusted life year (QALY) saved. This would be the first time in the Netherlands for a drug not to be reimbursed for financial reasons.
Nivolumab, which is used to treat squamous cell lung cancer, is made by Bristol-Myers Squibb and until now has been provided free by the company. It was approved by the European …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.